You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

BTK Inhibitors for CLL and MCL: A Settling Storm or Just the Beginning?

  • Authors: Deborah Stephens, DO; Chan Cheah, MBBS, FRACP, FRCPA, DMSc; Barbara F. Eichhorst, MD; Nirav N. Shah, MD
  • CME / ABIM MOC Released: 12/28/2022
  • Valid for credit through: 12/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists and pathologists.

The goal of this activity is to enable learners to better understand the recent data on Bruton tyrosine kinase (BTK) inhibitors and how they may change practice in managing patients with B-cell malignancies (eg, chronic lymphocytic leukemia [CLL]/small lymphocytic leukemia [SLL] and mantle cell lymphoma [MCL]).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current challenges with available BTK inhibitors in patients with B-cell malignancies
    • Emerging clinical trial data on BTK inhibitors in B-cell malignancies
  • Demonstrate greater confidence in their ability to
    • Integrate the latest data with BTK inhibitors into the treatment algorithm for patients with B-cell malignancies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Deborah Stephens, DO

    Associate Professor
    Director
    CLL and Lymphoma Program
    Division of Hematology and Hematologic Malignancies
    University of Utah
    Huntsman Cancer Institute
    Salt Lake City, Utah, United States

    Disclosures

    Deborah Stephens, DO, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; Celgene Corporation; CSL Behring; Genentech; Lilly; TG Therapeutics, Inc.
    Research funding from: Acerta; ArQule; AstraZeneca Pharmaceuticals LP; Juno Therapeutics, Inc.; Mingsight; Newave; Novartis

  • Chan Cheah, MBBS, FRACP, FRCPA, DMSc

    Consultant Hematologist
    Sir Charles Gairdner Hospital
    Perth, Australia

    Disclosures

    Chan Cheah, MBBS, FRACP, FRCPA, DMSc, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen; Merck Sharp & Dohme; Novartis; Roche; TG Therapeutics, Inc.
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Roche
    Research funding from: AbbVie, Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Loxo Oncology; Merck Sharp & Dohme; Roche

  • Barbara F. Eichhorst, MD

    Associate Professor
    Consultant Hematologist
    Department for Internal Medicine
    Secretary of the German Low-Grade Lymphoma Study Group
    University Hospital of Cologne
    Cologne, Germany

    Disclosures

    Barbara F. Eichhorst, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; Eli Lilly and Company; Janssen; Merck Sharp & Dohme
    Speaker or member of speakers bureau for: AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Janssen; Merck Sharp & Dohme; Roche
    Research funding from: AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Gilead Sciences, Inc.; Janssen; Roche

  • Nirav N. Shah, MD

    Associate Professor
    Medical College of Wisconsin
    Brookfield, Wisconsin, United States

    Disclosures

    Nirav N. Shah, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; Epizyme; Incyte Corporation; Kite Pharma, Inc.; Lilly Oncology; Miltenyi Biotec; Novartis; TG Therapeutics, Inc.
    Research funding from: Lilly Oncology; Miltenyi Biotec

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

BTK Inhibitors for CLL and MCL: A Settling Storm or Just the Beginning?

Authors: Deborah Stephens, DO; Chan Cheah, MBBS, FRACP, FRCPA, DMSc; Barbara F. Eichhorst, MD; Nirav N. Shah, MDFaculty and Disclosures

CME / ABIM MOC Released: 12/28/2022

Valid for credit through: 12/28/2023

processing....

PDF scaricabile in italiano

Download the pdf.

 

« Return to: BTK Inhibitors for CLL and MCL: A Settling Storm or Just the Beginning?
  • Print